318 related articles for article (PubMed ID: 23601496)
1. B-Cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease.
Elder ME; Nayak S; Collins SW; Lawson LA; Kelley JS; Herzog RW; Modica RF; Lew J; Lawrence RM; Byrne BJ
J Pediatr; 2013 Sep; 163(3):847-54.e1. PubMed ID: 23601496
[TBL] [Abstract][Full Text] [Related]
2. High Sustained Antibody Titers in Patients with Classic Infantile Pompe Disease Following Immunomodulation at Start of Enzyme Replacement Therapy.
Poelman E; Hoogeveen-Westerveld M; Kroos-de Haan MA; van den Hout JMP; Bronsema KJ; van de Merbel NC; van der Ploeg AT; Pijnappel WWMP
J Pediatr; 2018 Apr; 195():236-243.e3. PubMed ID: 29428273
[TBL] [Abstract][Full Text] [Related]
3. Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort.
Desai AK; Baloh CH; Sleasman JW; Rosenberg AS; Kishnani PS
Front Immunol; 2020; 11():1727. PubMed ID: 32849613
[TBL] [Abstract][Full Text] [Related]
4. Optimizing treatment outcomes: immune tolerance induction in Pompe disease patients undergoing enzyme replacement therapy.
Chen HA; Hsu RH; Fang CY; Desai AK; Lee NC; Hwu WL; Tsai FJ; Kishnani PS; Chien YH
Front Immunol; 2024; 15():1336599. PubMed ID: 38715621
[TBL] [Abstract][Full Text] [Related]
5. A Race Against Time-Changing the Natural History of CRIM Negative Infantile Pompe Disease.
Gupta P; Shayota BJ; Desai AK; Kiblawi F; Myridakis D; Messina J; Tah P; Tambini-King L; Kishnani PS
Front Immunol; 2020; 11():1929. PubMed ID: 33013846
[TBL] [Abstract][Full Text] [Related]
6. High dose IVIG successfully reduces high rhGAA IgG antibody titers in a CRIM-negative infantile Pompe disease patient.
Rairikar M; Kazi ZB; Desai A; Walters C; Rosenberg A; Kishnani PS
Mol Genet Metab; 2017 Sep; 122(1-2):76-79. PubMed ID: 28648664
[TBL] [Abstract][Full Text] [Related]
7. A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease.
Wang Z; Okamoto P; Keutzer J
Mol Genet Metab; 2014 Feb; 111(2):92-100. PubMed ID: 24044919
[TBL] [Abstract][Full Text] [Related]
8. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease.
Messinger YH; Mendelsohn NJ; Rhead W; Dimmock D; Hershkovitz E; Champion M; Jones SA; Olson R; White A; Wells C; Bali D; Case LE; Young SP; Rosenberg AS; Kishnani PS
Genet Med; 2012 Jan; 14(1):135-42. PubMed ID: 22237443
[TBL] [Abstract][Full Text] [Related]
9. Teaching tolerance: New approaches to enzyme replacement therapy for Pompe disease.
Cousens LP; Mingozzi F; van der Marel S; Su Y; Garman R; Ferreira V; Martin W; Scott DW; De Groot AS
Hum Vaccin Immunother; 2012 Oct; 8(10):1459-64. PubMed ID: 23095864
[TBL] [Abstract][Full Text] [Related]
10. Effects of higher and more frequent dosing of alglucosidase alfa and immunomodulation on long-term clinical outcome of classic infantile Pompe patients.
Poelman E; van den Dorpel JJA; Hoogeveen-Westerveld M; van den Hout JMP; van der Giessen LJ; van der Beek NAME; Pijnappel WWMP; van der Ploeg AT
J Inherit Metab Dis; 2020 Nov; 43(6):1243-1253. PubMed ID: 32506446
[TBL] [Abstract][Full Text] [Related]
11. Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT.
Banugaria SG; Prater SN; Patel TT; Dearmey SM; Milleson C; Sheets KB; Bali DS; Rehder CW; Raiman JA; Wang RA; Labarthe F; Charrow J; Harmatz P; Chakraborty P; Rosenberg AS; Kishnani PS
PLoS One; 2013; 8(6):e67052. PubMed ID: 23825616
[TBL] [Abstract][Full Text] [Related]
12. Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance.
Sun B; Bird A; Young SP; Kishnani PS; Chen YT; Koeberl DD
Am J Hum Genet; 2007 Nov; 81(5):1042-9. PubMed ID: 17924344
[TBL] [Abstract][Full Text] [Related]
13. CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy.
Berrier KL; Kazi ZB; Prater SN; Bali DS; Goldstein J; Stefanescu MC; Rehder CW; Botha EG; Ellaway C; Bhattacharya K; Tylki-Szymanska A; Karabul N; Rosenberg AS; Kishnani PS
Genet Med; 2015 Nov; 17(11):912-8. PubMed ID: 25741864
[TBL] [Abstract][Full Text] [Related]
14. Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease.
van Gelder CM; Hoogeveen-Westerveld M; Kroos MA; Plug I; van der Ploeg AT; Reuser AJ
J Inherit Metab Dis; 2015 Mar; 38(2):305-14. PubMed ID: 24715333
[TBL] [Abstract][Full Text] [Related]
15. Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience.
Bali DS; Goldstein JL; Banugaria S; Dai J; Mackey J; Rehder C; Kishnani PS
Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):40-9. PubMed ID: 22252923
[TBL] [Abstract][Full Text] [Related]
16. Effects of immunomodulation in classic infantile Pompe patients with high antibody titers.
Poelman E; Hoogeveen-Westerveld M; van den Hout JMP; Bredius RGM; Lankester AC; Driessen GJA; Kamphuis SSM; Pijnappel WWM; van der Ploeg AT
Orphanet J Rare Dis; 2019 Mar; 14(1):71. PubMed ID: 30902109
[TBL] [Abstract][Full Text] [Related]
17. Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells.
Banugaria SG; Patel TT; Mackey J; Das S; Amalfitano A; Rosenberg AS; Charrow J; Chen YT; Kishnani PS
Mol Genet Metab; 2012 Apr; 105(4):677-80. PubMed ID: 22365055
[TBL] [Abstract][Full Text] [Related]
18. Effects of immune modulation therapy in the first Croatian infant diagnosed with Pompe disease: a 3-year follow-up study.
Markic J; Polic B; Stricevic L; Metlicic V; Kuzmanic-Samija R; Kovacevic T; Ivkosic IE; Mestrovic J
Wien Klin Wochenschr; 2014 Feb; 126(3-4):133-7. PubMed ID: 24337590
[TBL] [Abstract][Full Text] [Related]
19. Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Pompe Disease.
De Groot AS; Desai AK; Lelias S; Miah SMS; Terry FE; Khan S; Li C; Yi JS; Ardito M; Martin WD; Kishnani PS
Front Immunol; 2021; 12():636731. PubMed ID: 34220802
[TBL] [Abstract][Full Text] [Related]
20. CRIM-negative infantile Pompe disease: 42-month treatment outcome.
Rohrbach M; Klein A; Köhli-Wiesner A; Veraguth D; Scheer I; Balmer C; Lauener R; Baumgartner MR
J Inherit Metab Dis; 2010 Dec; 33(6):751-7. PubMed ID: 20882352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
